Please assess the completion status of the following clinical trial:

Trial Title: Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed melanoma~  * Stage III or IV disease~* Must have at least two resectable tumors or a tumor large enough to undergo pre-treatment core needle biopsy~* Must be eligible for resection of disease with curative or palliative intent~PATIENT CHARACTERISTICS:~* ECOG performance status 0 or 1~* ANC ≥ 1,000/mm³~* Platelet count ≥ 50,000/mm³~* AST/ALT ≤ 3 times upper limit of normal (ULN)~* Total bilirubin normal~* Calculated creatinine clearance ≥ 50 mL/min~* INR ≤ 25% of ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 48 hours after completion of study treatment~* No history of allergic reaction to riluzole or similar compounds~* No known history of hepatitis B or C~PRIOR CONCURRENT THERAPY:~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).